Literature DB >> 8658601

Twenty-year follow-up on the effect of HLA matching on kidney transplant survival and prediction of future twenty-year survival.

P I Terasaki1, Y Cho, S Takemoto, M Cecka, D Gjertson.   

Abstract

The difficulty in achieving long-term survival is demonstrated by the fact that an improvement of 30 percentage points in 1-year cadaver donor survival resulted in only a 10-percentage point improvement over 20 years. In early transplants from 1965 to 1974, the 20-year survival rate of HLA identical siblings was 46%, of parental donors 27%, and of cadaver donors 12%. More recent grafts, performed since 1987, had a projected survival of 57% for identical donors, 30% for parental donors, and 18% for cadaver donors. With respect to HLA matching for cadaver donor kidney transplants, a 0 AB-antigen mismatch produced higher graft survival than did mismatched transplants during the 20-year period from 1965 to 1984. After the introduction of HLA Class II typing in 1980 and general improvements in typing for transplants performed after 1987, the 0 ABDR-mismatched grafts have a projected 20-year survival of 40%. The projected survival rates for transplants with one or more mismatches fall progressively to 13% for transplants that have 6 ABDR mismatches. Thus, the success due to HLA matching has improved ever since the introduction of cyclosporine because of the concurrent improvements in tissue typing for Class I and Class II specificities.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8658601

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  6 in total

Review 1.  Calcineurin inhibitors in HLA-identical living related donor kidney transplantation.

Authors:  Priya S Verghese; Ty B Dunn; Srinath Chinnakotla; Kristin J Gillingham; Arthur J Matas; Michael S Mauer
Journal:  Nephrol Dial Transplant       Date:  2014-01       Impact factor: 5.992

2.  Long-term unexpected consequence of two kidney transplants with full-match grafts: a report of two cases.

Authors:  Erhan Tatar; Adam Uslu; Ahmet Aykas; Tamer Sahin
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 3.  The HLA system: genetics, immunology, clinical testing, and clinical implications.

Authors:  Sung Yoon Choo
Journal:  Yonsei Med J       Date:  2007-02-28       Impact factor: 2.759

Review 4.  Unraveling the Role of Allo-Antibodies and Transplant Injury.

Authors:  Yoshiko Matsuda; Minnie M Sarwal
Journal:  Front Immunol       Date:  2016-10-21       Impact factor: 7.561

5.  Long-term mycophenolate monotherapy in human leukocyte antigen (HLA)-identical living-donor kidney transplantation.

Authors:  Blanca Gascó; Ignacio Revuelta; Ana Sánchez-Escuredo; Miquel Blasco; Federico Cofán; Nuria Esforzado; Luis F Quintana; María José Ricart; José Vicente Torregrosa; Josep M Campistol; Federico Oppenheimer; Fritz Diekmann
Journal:  Transplant Res       Date:  2014-02-03

6.  Mycophenolate Monotherapy in HLA-Matched Kidney Transplant Recipients: A Case Series of 20 Patients.

Authors:  Anthony J Hennes; Kimberly E Holdener; William J Burlingham; Didier A Mandelbrot; Sandesh Parajuli; Maha A Mohamed; Neetika Garg; Fahad Aziz; Brad C Astor; Arjang Djamali
Journal:  Transplant Direct       Date:  2020-01-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.